Author: aracila

Dimer Diabetes conference and the Global NASH/MASH Council in Istanbul, Turkey

This year’s Annual DIMER DIABETES conference (November 21-23, 2024) was organized by Professor Mustafa Kanat (GNC Member) in Istanbul, Turkey. This superb international conference covered a large number of topics associated with diabetes, including MASH. The Global NASH/MASH Council was represented by Dr. Zobair Younossi who provided a comprehensive overview of MASLD including disease burden, risk stratification and treatment of MASH. He also encouraged global collaboration in MASH across subspecialties of hepatology/gastroenterology, endocrinology, cardiology, nephrology and other important areas.

The Global NASH/MASH Council and Global Liver Council met during the AASLD 2024 annual meeting in San Diego, CA, USA

Sponsored by the Center for Outcomes Research in Liver Disease, the Global NASH/MASH Council (GNC) and the Global Liver Council (GLC) held their annual meeting on Sunday November 17th, 2024 at the AASLD 2024 conference. There were 93 members who attended (73 in person and 20 via virtual meeting) representing 29 different countries from across the globe. The leaders included those with expertise in hepatology, gastroenterology, endocrinology, primary care, pediatrics, nutrition, public health, public policy, patient advocacy and research. Several important issues related to MASLD, ALD, Met-ALD, Pediatric MASLD, Viral Hepatitis and Patient advocacy were discussed. In addition to participation in the GNC/GLC meeting, members presented multiple scientific papers during the meeting. Together these presentations help to meet the goals of the GNC/GLC which are to address and promote better understanding of the burden of different liver diseases across the globe. Through the inclusion of members from different regions of the world into our projects, we seek to gain a broader understanding of local, regional and global challenges and opportunities in different liver diseases across the world.

The Global NASH/MASH Council presentation at the APASL STC in Almaty, Kazakhstan, 2024

It was a pleasure to participate in the Asian Pacific Association for the Study of the Liver (APASL) Single Topic Conference "Liver Cirrhosis: Common and Rare Complications". This highly successful scientific meeting was organized in Almaty, Kazakhstan (November 1st-2nd, 2024) by the Kazakh Association for the Study of the Liver (KASL) and Armenian Association for the Study of the Liver (ARASL) in collaboration with APASL. As a member of the Global NASH Council (GNC), Dr. Younossi presented a “State of the Art Lecture” about future global collaborations in areas of MASLD and other liver diseases with increased engagement from the region. We are grateful for the leadership of Professor Alexander V. Nersesov and Professor Hasmik L. Ghazinyan (both members of GNC) for organizing this outstanding scientific meeting and for their hospitality. GNC and its collaborative members from the region will be carrying out multiple projects to better understand the challenges and opportunities of different liver diseases in this important region of the world.

GNC meeting at Saudi Association for Liver Diseases and Transplantation Conference, Riyadh, 2024

The Global NASH Council (GNC) had a very successful meeting during the annual meeting of the Saudi Society for the Study of Liver Disease and Transplantation and Saudi Liver Meeting on October 19, 2024. Experts from Saudi Arabia, the golf region, and GNC presented up to date information about the burden and management of MASLD in the region. GNC and its collaborative members will be carrying out multiple projects to better understand the challenges and opportunities of MASLD and other liver diseases in this important region of the world. https://www.globalnashcouncil.org/wp-content/uploads/2024/10/SASLT_SLM_2024_0.mp4

MASH Alliance Educational Portal

The Chronic Liver Disease Foundation (CLDF), Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), and Global NASH Council (GNC) have joined forces to launch a new educational effort for healthcare providers who manage metabolic dysfunctional-associated steatohepatitis (MASH). The mission of the MASH Alliance is to provide the most current, high-quality MASH-related medical education across multiple platforms to assist healthcare providers and stakeholders in making the best possible decisions for patients at risk or suffering from MASH. Learn More

The Global NASH/MASH Council met during the ALEH 2024 annual meeting in Santiago, Chile

The Global NASH/MASH Council was hosted by The Latin American Association for the Study of the Liver (ALEH) during ALEH annual meeting from September 9th-11, 2024 in Santiago, Chile. The GNC meeting was well attended by leaders from the region and established several joint projects from the region. Inclusion of members of ALEH into GNC/GLC projects is crucial to better understand the challenges and opportunities of different liver diseases in this important region of the world.

The Global NASH Council Newsletter Edition 7 June 2024

Dear Colleagues, We hope this message finds you well. We're excited to share the latest GNC updates with you through our newsletter. In this edition, we have included updates on: Our Global Liver Registry programs Recent GNC meetings Current project activities Presentations to scientific societies We greatly appreciate your contributions and active participation! We look forward to our continued collaboration. Best regards, The Global NASH Council

Annual Meeting of the Global NASH Council (GNC) and Global Liver Council (GLC) June 8, 2024, ILC 2024, Milan Italy

This year, we had a highy successful GNC/GLC meeting during EASL 2024 in Milan, Italy which was attended by 77 members (65 in person and 12 via zoom). These members represented leaders in the field of liver disease, endocrinology, nutrition and patient representatives from most regions of the world. During the meeting, an overview of the growth and activities of the Councils and a summary of the large scale projects undertaken by the Council members were provided. These projects included the results of the Global NAFLD Stigma survey from patients and providers, the impact of the nomencalture change on evidence (mortality outcomes, NITs and PROs), initial results of the large mega-analysis of 16,000 liver biopsies from MASLD patients, Cost of Inaction about MASLD (Economic burden of MASLD) in 6 countries (US, Germany, Japan, Spain, Saudi Arabia and Brazil), NIT Threshold Global Survey and Enhancing the Implementation of MASLD/MASH Guidelines Across the Globe (EIMG). Furthermore, co-chairs of each of the 10 committees of GNC/GLC provided their reports and future plans. Academic productivity and future regional meetings were discussed.

Scientific Presentations at the International Liver Congress 2024, Milan, Italy

This week members of the Global NASH Council and Global Liver Council will be sharing 11 research presentations at the International Liver Congress 2024 in Milan, Italy. Also, members pf GNC are actively participating as faculty in different scientific programs of ILC 2024. Cost of inaction for metabolic dysfunction-associated steatohepatitis (MASH): the projected economic burden in the United States, Zobair M Younossi, Jeffrey V. Lazarus, Alina M. Allen, Kenneth Cusi, Frank Tacke, Michael Roden, Jorn M. Schattenberg, Henry E. Mark, Linda Henry, Fatema Nader, James Paik. Prevalence and mortality of the spectrum of steatotic liver disease (SLD) in the US populations, Zobair M Younossi, Linda Henry, Pegah Golabi, Leyla de Avila, Ryuki Hashida, James Minhui Paik. Association of Quantitative Hepatic Collagen with Non-Invasive Tests (NITs) for Fibrosis in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD), Zobair M Younossi, James M. Estep, Sean C. Felix, Brian P. Lam, Daisong Tan, Aaron B. Koenig, Fanny Monge, Andrei Racila, Zachary Goodman, Maria Stepanova. Association of non-invasive tests (NITs) with genetic polymorphism in patients with metabolic dysfunction–associated steatotic liver disease (MASLD), Zobair M Younossi, James M. Estep, Zohal Zekrya, Sean C. Felix, Brian P. Lam, Zaid Younossi, Andrei Racila, Maria Stepanova. Food swamps and easy access to unhealthy food increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) mortality in the United States (U.S.), Annette Paik, Linda Henry, Leyla de Avila, Saleh Alqahtani, Fatema Nader, James Minhui Paik, Zobair M Younossi. Associations of food insecurity and healthcare access with the prevalence and mortality of metabolic dysfunction-associated steatotic liver disease (MASLD): a global study of the United Nation and the global burden of disease data, Zobair M Younossi, Shira Zelber-Sagi, Carina Kugelmas, Jeffrey V. Lazarus, Annette Paik, Leyla de Avila, Lynn Gerber, James Minhui Paik Health-Related Quality of Life (HRQL) assessments in a 52-Week, double-blind, randomized, placebo-controlled phase 3 study of Resmetirom (MGL-3196) in patients with nonalcoholic steatohepatitis (NASH) and fibrosis (MAESTRO-NASH), Zobair M Younossi, Maria Stepanova, Andrei Racila, Linda Henry, Keith Miller, Dominic Labriola, Rebecca A Taub, Fatema Nader. Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Zobair M Younossi, Yusuf Yilmaz, Ming-Lung Yu, Vasily Isakov, Marlen Castellanos-Fernandez, Vincent Wai-Sun Wong, Yuichiro Eguchi, Manuel Romero-Gomez, Nahum Mendez-Sanchez, Ajay Duseja, Caglayan Keklikkiran, Jacob George, Elisabetta Bugianesi, Ashwani K. Singal, Saeed S Hamid, Khalid Aida Alswat, Wah Kheong Chan, Jian-Gao Fan, George A Papandreou, Stuart C. Gordon, Mohamed El Kassas, Stuart Roberts, Brian P. Lam, Andrei Racila, Linda Henry, Saleh Alqahtani, Maria Stepanova. In Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Clinically Significant Pruritus is Associated with High Serum Bile Acid (BA) Level and Advanced Fibrosis (AF), Zobair M Younossi, James M. Estep, Sean C. Felix, BP. Lam, Sumanta Mukherjee, Brandon Swift, Linda Casillas, Andrea Ribeiro, Jake Hunnicutt, Megan Mclaughlin, A Racila, Fatema Nader, Maria Stepanova Development and validation of CLDQ-MASH: a disease specific health related quality of life instrument for patients with metabolic dysfunction-associated steatohepatitis (MASH), Zobair M. Younossi, Maria Stepanova, Issah Younossi, Andrei Racila. Assessments of health utilities in patients with metabolic dysfunction-associated steatohepatitis (MASH): cross-walk between CLDQ-NASH, SF-6D, and the EuroQol EQ-5D, Zobair M Younossi, Maria Stepanova, Jesse Fishman, James Dodge, Dominic Labriola, Rebecca A Taub, Fatema Nader.